Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

X
Trial Profile

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atezolizumab (Primary) ; Bevacizumab (Primary) ; Muzastotug (Primary) ; NKT 2152 (Primary) ; Tiragolumab (Primary) ; Tobemstomig (Primary) ; Tocilizumab (Primary) ; TPST-1120 (Primary)
  • Indications Liver cancer
  • Focus Therapeutic Use
  • Acronyms Morpheus-Liver
  • Sponsors Roche
  • Most Recent Events

    • 22 May 2024 Planned End Date changed from 27 Dec 2025 to 31 Aug 2026.
    • 22 May 2024 Planned primary completion date changed from 27 Dec 2025 to 31 Aug 2026.
    • 08 Dec 2023 According to a NiKang Therapeutics media release, patient enrollment of NKT2152 in combination with standard-of-care atezolizumab (Tecentriq) and bevacizumab (Avastin) will begin in 2024.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top